Search

Becton Dickinson and Co

Closed

SectorHealthcare

183.41 0.86

Overview

Share price change

24h

Current

Min

180.71

Max

183.72

Key metrics

By Trading Economics

Income

759M

449M

Sales

269M

5B

P/E

Sector Avg

30.601

57.002

EPS

3.23

Dividend yield

2.37

Profit margin

9.011

Employees

72,000

EBITDA

-23M

686M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+4.58% upside

Dividends

By Acuity

Dividend yield

Sector Avg

2.37%

2.22%

Next Earnings

5 lis 2026

Next Dividend date

30 wrz 2026

Next Ex Dividend date

9 wrz 2026

Market Stats

By TradingEconomics

Market Cap

3.3B

49B

Previous open

182.55

Previous close

183.41

News Sentiment

By Acuity

21%

79%

67 / 340 Ranking in Healthcare

Becton Dickinson and Co Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

14 sie 2026, 19:36 UTC

Becton Dickinson is trading higher today, despite a reported decline in retail sales for July that raised concerns about consumer demand.

13 sie 2026, 22:01 UTC

Becton Dickinson shares are lower in after-market hours, continuing a decline from Thursday's close amid overall weakness in after-hours trading.

12 sie 2026, 23:46 UTC

Event

Becton Dickinson announced successful enrollment completion in the PREVENT clinical trial for Phasix™ Mesh. Shares remain roughly flat in after-market trading.

11 sie 2026, 22:26 UTC

Becton Dickinson is trading lower in after-market hours, reversing an initial gain. No specific news was identified to explain this price movement.

10 sie 2026, 19:43 UTC

News

Becton Dickinson reports EPS of $3.23, exceeding estimates, and updates fiscal 2026 guidance, driving shares higher amid strong health care equipment sector gains.

7 sie 2026, 21:11 UTC

News

Citigroup maintained its Buy rating on Becton Dickinson and raised its price target to $204, contributing to the stock's higher after-market trading.

6 sie 2026, 23:01 UTC

Becton Dickinson and Co shares are higher in after-market hours, continuing a trend of three consecutive daily gains and remaining above the 20-day moving average.

5 sie 2026, 19:46 UTC

Becton Dickinson shares are lower today amid broader market declines influenced by ADP's report on private sector job growth miss for July.

4 sie 2026, 23:16 UTC

Becton Dickinson shares higher in after-market trading, reflecting positive market sentiment amid falling crude oil prices and expectations of reduced inflationary pressures.

3 sie 2026, 22:51 UTC

Becton Dickinson shares are lower in after-market trading, influenced by a significant downturn in the Health Care Equipment sub-sector.

31 lip 2026, 19:46 UTC

Becton Dickinson is higher today, showing resilience amid rising bond yields and inflation concerns. The stock remains above its 20-day moving average.

30 lip 2026, 22:51 UTC

Becton Dickinson and Co shares are lower in after-hours trading, reflecting broader weakness in the Health Care Equipment sub-sector.

29 lip 2026, 23:56 UTC

Becton Dickinson and Co shares are higher in after-market hours, maintaining momentum from Wednesday's close amid uncertainty over future interest rate decisions.

28 lip 2026, 20:02 UTC

News

UBS initiated coverage of Becton Dickinson with a Buy rating and $190 price target, contributing to the stock's upward movement this week.

27 lip 2026, 20:06 UTC

Becton Dickinson shares are higher, reflecting strength near the upper end of their one-month range amid falling oil prices and declining Treasury yields.

24 lip 2026, 19:26 UTC

Becton Dickinson and Co is trading higher, supported by gains in the Health Care Equipment sub-sector and maintaining a position above its 20-day moving average.

23 lip 2026, 19:56 UTC

Becton Dickinson shares are lower, extending a five-session decline amid ongoing market concerns over corporate earnings and inflation pressures from rising oil prices.

21 lip 2026, 19:36 UTC

Becton Dickinson is trading lower today, extending a trend of three consecutive daily declines. No specific news was identified to explain the movement.

20 lip 2026, 20:14 UTC

Becton Dickinson remains roughly flat in after-market trading, positioned 1.12% above its 20-day moving average, but has declined for three consecutive sessions.

Peer Comparison

Price change

Becton Dickinson and Co Forecast

Price Target

By TipRanks

4.58% upside

12 Months Forecast

Average 191.8 USD  4.58%

High 210 USD

Low 175 USD

Based on 10 Wall Street analysts offering 12 month price targets forBecton Dickinson and Co - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

10 ratings

5

Buy

5

Hold

0

Sell

Sentiment

By Acuity

67 / 340 Ranking in Healthcare

News Sentiment

Very Strong Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Becton Dickinson and Co

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.
help-icon Live chat